EICHORPublic-registry site landscape for NCT04040816, “Placebo Controlled, Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAP-001 in Gout Patients”, a Gout study sponsored by Shanton Pharma Co., Ltd.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT04040816 (registry record) |
| Study title | Placebo Controlled, Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAP-001 in Gout Patients |
| Official title | A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAP-001 in Gout Patients With Hyperuricemia |
| Sponsor | Shanton Pharma Co., Ltd. |
| Condition(s) | Gout; Hyperuricemia |
| Phase | PHASE2 |
| Listed sites | 6 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT04040816.
Eichor generates a preliminary site-risk snapshot for NCT04040816 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Gout trials
← Eichor home · All tracked trials · Gout studies · Weekly briefs
